NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Market Cap	$1.42B	P/E Ratio	N/A
52W High	$34.13	52W Low	$10.70
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-40.7%	52W Position	11.2%
Overall Score	58	Value Score	60
Quality Score	42	Technical Score	72

EPS Current Est	$-1.39	EPS Next Est	$-1.46
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVCR	$13.32	-2.49%	1.16M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVCR	$13.32	-2.5%	1.16M
3
4
5
6

NVCR

NVCR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get NovoCure Limited Data in Excel

Get NovoCure Limited Data in Excel